Gabapentin to control seizures in children undergoing cancer treatment

Journal of Child Neurology

Volumn 19, Issue 2, 2004, Pages 97-101

  Khan, Raja B ^a   Hunt, Daniel L ^a   Thompson, Stephen J ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; GABAPENTIN; METHOTREXATE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADD ON THERAPY; ADOLESCENT; ARTICLE; BRAIN CANCER; CANCER RADIOTHERAPY; CHILD; CHILD CARE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE CONTROL; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INFANT; IRRITABILITY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; NEUROLOGIC DISEASE; PREDICTION; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME;

EID: 1842433789     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738040190020301     Document Type: Article

References (20)

1. Winick NJ, Bowman WP, Kamen BA, et al: Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992;84:252-256.
2. Ochs JJ, Bowman WP, Pui CH, et al: Seizures in childhood lymphoblastic leukaemia patients. Lancet 1984;2:1422-1424.
3. Mahoney DH Jr, Shuster JJ, Nitschke R, et al: Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 2000;18:1285-1294.
4. Pace A, Bove L, Innocenti P, et al. Epilepsy and gliomas: Incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998; 17:479-482.
5. Villikka K, Kivisto KT, Maenpaa H, et al: Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999;66:589-593.
6. Zamboni WC, Gajjar AJ, Heideman RL, et al: Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998;4:783-789.
7. Williams ML, Wainer IW, Embree L, et al: Enantioselective induction of cyclophosphamide metabolism by phenytoin. Chirality 1999;11:569-574.
8. Grossman SA, Hochberg F, Fisher J, et al: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998;42:118-126.
9. Relling MV, Pui CH, Sandlund JT, et al: Adverse effect of anti-convulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285-290.
10. Khafaga YM, Jamshed A, Allam AA, et al: Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy. Acta Oncol 1999;38:111-116.
11. Beydoun A: Monotherapy trials with gabapentin for partial epilepsy. Epilepsia 1999;40(Suppl 6):S13-S16.
12. Brodie MJ, Chadwick DW, Anhut H, et al: Gabapentin versus lamotrigine monotherapy: A double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000.
13. Chadwick DW, Anhut H, Greiner MJ, et al: A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998;51:1282-1288.
14. Berry DJ, Beran RG, Plunkeft MJ, et al: The absorption of gabapentin following high dose escalation. Seizure 2003;12:28-36.
15. Nelder JA, Wedderburn RWM: Generalized linear models. J R Stat Soc 1972;A135:370-384.
16. MacDonald B: The prognosis of epilepsy. Seizure 2001;10:347-358.
17. Kwan P, Brodie MJ: Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
18. Hauser E, Freilinger M, Seidl R, Groh C: Prognosis of childhood epilepsy in newly referred patients. J Child Neurol 1996;11:201-204.
19. Moots PL, Maciunas RJ, Eisert DR, et al: The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995;52:717-724.
20. Glantz MJ, Cole BF, Forsyth PA, et al: Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-1893.